



The Open Microbiology Journal

Content list available at: <https://openmicrobiologyjournal.com>



RESEARCH ARTICLE

Comparison of Effectiveness of Germania Honey Compared to Manuka Honey in Methicillin-Resistant *Staphylococcus aureus* (MRSA) Killing

Ali M. Bazzi^{1*}, Ali A. Rabaan², Jaffar A. Al-Tawfiq³ and Bilal M. Shannak¹

¹Microbiology Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia

²Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia

³Specialty Internal Medicine and Quality Department, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia and Indiana University School of Medicine, Indiana, USA; Johns Hopkins University School of Medicine, Baltimore, MD, USA

Abstract:

Purpose:

Manuka honey is currently used in medical-grade sterile wound treatment products and has been shown to be effective in methicillin-resistant *Staphylococcus aureus* (MRSA) killing *in vitro* and in wound healing in a number of case studies and series. Locally produced honey in Pakistan and Chile have been proposed to be as effective as Manuka honey in bacterial killing *in vitro*, presenting potentially more accessible and affordable alternatives. In this study, we compared the effectiveness of a local Germania honey from Saudi Arabia to Manuka honey MGO 550 for *in vitro* killing of MRSA.

Methodology:

Overnight Muller Hinton broth cultures of 50 wound culture isolates of MRSA from 50 patients were incubated with a series of dilutions of Manuka honey MGO 550 and corresponding Germania honey dilutions for 24 h. Turbidity was assessed to determine whether bacterial growth had occurred, and no growth was confirmed by a further 24 h sub-culture on blood agar.

Results/Key findings:

Manuka honey MGO 550 was significantly more effective than Germania honey at MRSA killing at 100% v/v, 50% v/v and 25% v/v ($p=0.025$, 0.000265, and 0.000112 respectively)

Conclusion:

Manuka honey MGO 550 is significantly more effective in killing MRSA *in vitro* than Germania honey. Germania honey does not appear to be a promising locally produced alternative to Manuka honey for the development of honey-based wound dressings. Further experiments could determine if Germania honey is effective against other bacterial species.

Keywords: Manuka honey, Germania honey, MRSA, Anti-bacterial, Skin and soft tissue infections, Wound.

Article History

Received: November 1, 2018

Revised: January 20, 2019

Accepted: January 26, 2019

1. INTRODUCTION

The rise in antimicrobial resistance in bacteria is a major worldwide public health issue. In the context of bacterial Skin and Skin Structure Infections (SSSI), Skin and Soft Tissue Infections (SSTI) and wound infections, methicillin-resistance *Staphylococcus aureus* (MRSA) is of particular concern; the emergence of Vancomycin-Intermediate *S. aureus* (VISA),

heterogeneous VISA, and vancomycin-resistant *S. aureus* (VRSA) strains has further reduced antibiotic options [1 - 4]. Prevalence of MRSA among SSSIs and SSTIs varies geographically but is generally high. For example, in a study on 471,550 SSTI episodes in Northern California between 2009 and 2011, *S. aureus* was the pathogen identified in 81% of pathogen-positive specimens, of which 46% were MRSA, while in a retrospective review of 200 *S. aureus* isolates, of which 87.3% were SSTIs, in the western region of Saudi Arabia between 2009 and 2010, MRSA was found in 39.5% of isolates [1, 5]. Other important antibiotic-resistant bacteria in

* Address correspondence to this author at the P.O. Box 76, Room 224, Building 62, Johns Hopkins Aramco Healthcare, Saudi Aramco, Dhahran 31311, Saudi Arabia; Tel: +966-13-870-6631; Fax: +966-13-877-6741; E-mails: bazziamh@gmail.com; ali.bazzi@jhah.com

SSTIs are *Enterobacteriaceae* including *Escherichia*, *Klebsiella*, *Citrobacter*, *Enterobacter* and *Serratia*, such as Carbapenem-Resistant *Enterobacteriaceae* (CRE) and extended spectrum β -lactamase (ESBL)-expressing *Enterobacteriaceae* [6 - 8]. *Pseudomonas aeruginosa* persists in chronic wounds due to the formation of biofilms and tolerance of many antimicrobial treatments is another serious public health issue [9]. The increasing prevalence of such infections has necessitated attempts to identify alternative antibiotic treatments and has also raised interest in non-antibiotic therapies.

Honey is an example of a remedy that has been used historically and in complementary medicine in wound dressings and is currently in use in sterile wound treatment products licenced in many countries [10, 11]. Most interest centres on Manuka honey, which is made from *Leptospermum scoparium* (Manuka) trees found in New Zealand and Australia [11, 12]. Antibacterial activity of many kinds of honey is related to levels of hydrogen peroxide; however, *Leptospermum* honey are relatively low in hydrogen peroxide and their antimicrobial activity correlates with levels of methyl glyoxal (MGO) which is produced by dehydration of dihydroxyacetone (DHA) from the nectar of the Manuka flowers [11 - 14]. While hydrogen peroxide or MGO are important elements of honey's antibacterial activity, other mediators may also play a part, including defensins, glycosides and phenolic antioxidant compounds [11].

Sterile Manuka honey-based products such as Medi-honey™ have been associated with infection clearance and wound healing in a number of case studies and series, for example in treatment of leg ulcers, as well as chronic Pressure Ulcers (PUs) in Spinal Cord-Injured (SCI) patients, wound care in pediatric oncology patients and prevention of pin site infections during open reduction with external fixation (OREF) for correction of Charcot deformity in diabetic patients [15 - 18]. Medical grade Manuka honey preparations have been shown to be effective *in vitro* against both biofilm and free-swimming bacteria, including MRSA and *Pseudomonas aeruginosa* [9, 19]. Synergism *in vitro* with rifampicin has also been observed against MRSA biofilms and free-swimming bacteria [20, 21]. The beneficial effects of Manuka honey in treating infection are mediated by various proposed mechanisms, including changes in gene and protein expression levels of mediators of bacterial ribosomal function, protein synthesis, stress responses, growth and metabolism [10, 22], down-regulation of expression of genes associated with virulence, cell division and the tricarboxylic acid cycle [23, 24] and reduction in expression of universal stress protein A [25].

Some studies have suggested that other locally produced kinds of honey from various regions including Pakistan and Chile are also effective antibacterial agents in *in vitro* studies [26, 27]. In this study, we compared the efficacy of local Germania honey from Saudi Arabia *versus* Manuka honey MGO 550 in the inhibition of growth of 50 MRSA patient samples.

2. MATERIALS AND METHODS

2.1. Bacterial Strains

50 wound culture isolates of MRSA from 50 patients were tested for sensitivity to either Manuka honey MGO 550 or a local Germania commercial honey product from Saudi Arabia. Clinical isolates were identified as MRSA using routine screening by Polymerase Chain Reaction (PCR) with the Xpert MRSA-SA Nasal Complete G3 kit. Overnight cultures of each strain were prepared in Muller Hinton broth. Antibiotic susceptibility profiles were determined according to the CLSI M100 2018 criteria [28]. Samples were primarily tested using an automated microbiology identification system (VITEK® 2; bioMérieux, Marcy-l'Étoile, France) system for sensitivity to the following antibiotics: penicillin, oxacillin, gentamicin, ciprofloxacin, levofloxacin, moxifloxacin, clindamycin, erythromycin, quinupristin, linezolid, vancomycin, tetracycline, tigecycline, nitrofurantoin, rifampicin and trimethoprim/sulfamethoxazole and for Inducible Clindamycin Resistance (ICR). VITEK-2 tests for sensitivity were performed by calculating the Minimum Inhibitory Concentration (MIC) for each antibiotic, and the interpretation of each MIC value was assessed based on the CLSI guidelines [28]. ATCC33591 strain was used as the control. Cefoxitin was also used to determine the presence or absence of MRSA.

2.2. Honey Samples

Manuka Honey stock solution was made by mixing 108 g of Manuka honey MGO 550 (1 g contains 550 μ g MGO) with 100 ml Muller Hinton broth to give a final MGO concentration of 600 μ g/ml. 100 mg catalase was added to the stock solution to neutralize hydrogen peroxide. A series of two-fold dilutions of the stock solution were carried out in honey-free Muller Hinton broth to give final concentrations of 600 μ g/ml (undiluted), 300 μ g/ml (50% v/v), 150 μ g/ml (25% v/v), 75 μ g/ml (12.5% v/v) and 37.5 μ g/ml (6.25% v/v) (1 ml per tube). A 0.5 McFarland suspension from each of the 50 overnight MRSA cultures was prepared and diluted to a cell density of 5×10^7 CFU/mL in 0.45 saline, and 5×10^5 CFU (10 μ l) of each diluted bacterial suspension was transferred to each of the Manuka honey MGO 550-containing tubes to give a final bacterial concentration 5×10^5 CFU/ml, as per CLSI guideline recommendations. A commercial local Germania honey stock solution was prepared, diluted, and inoculated in the same way as for Manuka honey for comparison purposes. Bacterial growth was assessed by checking for turbidity in Muller Hinton broth after 24 h of culture. We used DensiCHEK™ Plus (bioMérieux) with the VITEK® 2 system to adjust the turbidity to zero after the samples were inoculated. 24 hours later, all samples that showed no growth by naked eye were confirmed using the DensiCHEK™ Plus device. For all tubes that were scored as clear, samples were sub-cultured on to blood agar plates which were incubated for a further 24 h to finally confirm no bacterial growth.

2.3. Data Analysis

To compare the distribution of growth *versus* non-growth results between Manuka honey MGO 550 and Germania honey at corresponding dilutions, Chi-squared analysis was used, with

$p \leq 0.05$ accepted as significant. Statistical analysis was performed using Social Sciences Statistics and GraphPad QuickCalcs online software.

3. RESULTS

The number of isolates for which growth or no growth occurred was scored for each dilution of Manuka honey MGO 550 and *Germania* honey (Table 1), (Fig. 1). Undiluted Manuka honey (600 µg/ml) was significantly more effective than undiluted locally sourced *Germania* honey against MRSA ($p=0.025$) Table 1; Fig. (1). At 50% v/v and 25% v/v dilutions, Manuka honey was also significantly more effective in bacterial killing ($p= 0.000265$ and 0.000112 respectively) Table 1; Fig. (1). At 12.5% v/v and 6.25% v/v, both honey types were equally ineffective (Fig. 1); (Table 1), thus Manuka honey MGO 550 at concentrations of 75 µg/ml MGO was

ineffective in MRSA killing *in vitro*.

Antibiotic resistance profiles for the 50 MRSA isolates are shown in Table 2. All strains were resistant to cefoxitin. 26 isolates had the same profile as the control ATCC33591 strain; the remaining 24 isolates were divided between seven further profiles. The number of isolates which grew in the presence of undiluted, 50% v/v, 25% v/v and 12.5% v/v dilutions for both Manuka and *Germania* honey was considered with respect to antibiotic resistance profile (Table 3). Consistent with the overall results, the growth of the dominant MRSA strain was significantly less on undiluted, 50% v/v and 25% v/v Manuka honey compared to *Germania* honey (Table 2). The small total number of isolates for each of the other antibiotic susceptibility profiles complicated analysis of any differences in effect between the two honey types (Tables 2 and 3).

Table 1. Chi square comparison of Manuka versus *Germania* honey on MRSA growth.

-	Bacterial Growth			Chi square statistic	-P value
	Yes	No	ATCC 33591		
Manuka 600 µg/ml (undiluted)	2	48	No growth	5.005	0.025
<i>Germania</i> undiluted stock	9	41	No growth		
Manuka 300 µg/ml (50% v/v)	5	45	No growth	13.306	0.000265
<i>Germania</i> (1/2 diluted) (50% v/v)	21	29	Growth		
Manuka 150 µg/ml (25% v/v)	11	39	No growth	14.923	0.000112
<i>Germania</i> 1/4 diluted (25% v/v)	30	20	Growth		
Manuka 75 µg/ml (12.5% v/v)	43	7	Growth	3.052	0.081
<i>Germania</i> 1/8 diluted (12.5% v/v)	48	2	Growth		
Manuka 37.5 µg/ml (6.25% v/v)	47	3	Growth	1.042	0.307
<i>Germania</i> 1/16 diluted (6.25% v/v)	49	1	Growth		




Fig. (1). Comparison of effects of Manuka versus *Germania* honey on MRSA growth.

Table 2. MRSA strain antibiotic susceptibility profiles.

-	Number of strains								Total
	26	4	5	3	5	1	4	2	
Antibiotic									
Penicillin	R	R	R	R	R	R	R	R	-
Oxacillin	R	R	R	R	R	R	R	R	-
Gentamicin	S	S	S	S	S	S	R	R	-
Ciprofloxacin	S	S	S	S	R	S	R	R	-
Levofloxacin	S	S	S	S	R	S	R	R	-
Moxifloxacin	S	S	S	S	S	S	S	R	-
Clindamycin	S	R	S	R	S	S	S	R	-
Erythromycin	S	R	S	R	S	S	S	R	-
Quinupristin	S	S	S	S	S	S	S	S	-
Linezolid	S	S	S	S	S	S	S	S	-
Vancomycin	S	S	S	S	S	S	S	S	-
Tetracycline	S	S	R	R	R	S	S	S	-
Tigecycline	S	S	S	S	S	S	S	S	-
Nitrofurantoin	S	S	S	S	S	S	S	S	-
Rifampicin	S	S	S	S	S	S	S	S	-
Trimethoprim/ sulfamethoxazole	S	S	S	S	S	R	S	S	-
ICR	NEG	POS	NEG	NEG	NEG	NEG	NEG	POS	-
	ATCC33591 control strain profile								

R: resistant; S: sensitive; ICR: inducible clindamycin resistance; POS: positive; NEG: negative

Table 3. Isolate growth numbers for different antibiotic susceptibility profiles.

-	Number of isolates with growth								Total
Man undiluted	2	0	0	0	0	0	0	0	2
Ger undiluted	7	2							9
Man 50% v/v	4	1	0	0	0	0	0	0	5
Ger 50% v/v	18	2	1						21
Man 50% v/v	8	2	0	0	1	0	0	0	11
Ger 50% v/v	25	2	1		2				30
Man 50% v/v	25	4	2	2	3	1	4	2	43
Ger 50% v/v	26	4	5	2	4	1	4	2	48
Antibiotic									
Penicillin	R	R	R	R	R	R	R	R	-
Oxacillin	R	R	R	R	R	R	R	R	-
Gentamicin	S	S	S	S	S	S	R	R	-
Ciprofloxacin	S	S	S	S	R	S	R	R	-
Levofloxacin,	S	S	S	S	R	S	R	R	-
Moxifloxacin	S	S	S	S	S	S	S	R	-
Clindamycin	S	R	S	R	S	S	S	R	-
Erythromycin	S	R	S	R	S	S	S	R	-
Quinupristin	S	S	S	S	S	S	S	S	-
Linezolid	S	S	S	S	S	S	S	S	-
Vancomycin	S	S	S	S	S	S	S	S	-
Tetracycline	S	S	R	R	R	S	S	S	-
Tigecycline	S	S	S	S	S	S	S	S	-
Nitrofurantoin	S	S	S	S	S	S	S	S	-
Rifampicin	S	S	S	S	S	S	S	S	-
Trimethoprim/ sulfamethoxazole	S	S	S	S	S	R	S	S	-
ICR	NEG	POS	NEG	NEG	NEG	NEG	NEG	POS	-

Man: Manuka; Ger: Germania; R: resistant; S: sensitive; ICR: inducible clindamycin resistance; POS: positive; NEG: negative

4. DISCUSSION

In this study, we compared the *in vitro* performance of a locally sourced Germania honey against Manuka honey MGO 550 in killing MRSA from patient wound infections. Consistent with previous findings, Manuka honey was effective in preventing the growth of MRSA down to a dilution of 25% v/v [9, 19, 27]. However, unlike some other kinds of honey, including black seed honey from Pakistan or Ulmo 90 honey from Chile, diluted Germania honey was relatively ineffective against MRSA and it was significantly less effective than Manuka honey even when undiluted [26, 27]. One recent study comparing locally produced black seed honeys from Pakistan to Manuka honey showed that while Manuka honey was more effective, with a lower Minimum Inhibitory Concentration (MIC), than the other honeys against 25 wound cultures of MRSA and standard strains of *S. aureus*, *P. aeruginosa* and *E. coli*, the differences were minimal [26]. Importantly, the locally produced honeys may represent a more accessible and affordable solution [26]. Results of another study on Chilean honey made from the Ulmo tree (Ulmo 90 honey) showed that in agar diffusion and MIC spectrophotometric studies the Ulmo 90 honey was more effective than UMF® 25+ honey against five MRSA isolates and equivalent for *P. aeruginosa* and *E. coli* strains [27]. By contrast, our locally produced Germania honey does not appear to be a good potential local alternative to use of Manuka honey in the treatment of MRSA in wound infections. Our data showed that Manuka honey was effective in the suppression of growth of MRSA strains that are resistant to either one or more than one class of antibiotics. Manuka honey was significantly more effective against strains with the dominant MRSA antibiotic resistance profile (penicillin and oxacillin resistant). However, there were insufficient numbers of isolates for each of the other seven antibiotic susceptibility profiles to definitively conclude if Manuka honey was also more effective for these strains.

Evidence from some studies supports the use of medical-grade honey-based dressings. A prospective observational study was carried out on treatment with Medihoney™ of 121 wounds of various aetiologies during a two-year period in ten hospitals in Germany and Austria [29]. Wound size and perceived pain decreased significantly in response to Medihoney™, wound healing was often rapid and there was less wound slough and/or necrosis [29]. Furthermore, in a pilot study on pin site infections in 21 diabetic patients undergoing Open Reduction with External Fixation (OREF) for correction of Charcot deformity, use of active *Leptospermum* honey-impregnated dressings significantly reduced the rate of infections [18]. However, other studies suggest caution is needed in the choice of honey-based dressings. For example, results of the randomized controlled HONEYPOT trial do not support the use of topical medical grade honey over topical mupirocin for prevention of exit site infection and peritonitis in adults on Peritoneal Dialysis (PD), although the possibility of benefit in pediatric patients would warrant further specific trials [30].

In Saudi Arabia, where this study was performed, MRSA represents a significant burden both within healthcare facilities and in the community, for example in SSTIs [1, 31 - 33].

Potentially, the use of medical grade Manuka honey could form a valuable adjunctive treatment along with antibiotics, consistent with experience in other countries. Bacterial biofilms are a particular problem in chronic wound infections, and the efficacy of Medihoney™ against biofilms has been shown *in vitro* [9, 19]. A recent study using MacSynergy II to study responsiveness of *S. aureus* biofilms to combinations of Medihoney™ and different antibiotics showed strong synergy between Medihoney™ and rifampicin in reduction of biofilm biomass and embedded cell viability [21]. The extent of the reduction would be likely to have *in vivo* significance [21]. The study also showed, however, that Medihoney™ at subinhibitory concentrations had antagonistic effects on clindamycin, gentamicin, and oxacillin treatment, indicating the importance of establishing effective concentrations and combinations. Synergism between rifampicin and Medihoney™ against MRSA and clinical isolates of *S. aureus* has also been shown in checkerboard microdilution assays, time-kill curve experiments and agar diffusion assays, along with a reduction in emergence of rifampicin-resistant *S. aureus in vitro*, suggesting that use of Medihoney™ as an adjunctive treatment could have benefits in reducing the risk of antibiotic resistance [20]. Other *in vitro* studies have shown that co-treatment with Manuka honey and oxacillin could synergistically inhibit MRSA *in vitro* and restore oxacillin sensitivity [34]. Cultivation of bacterial strains including MRSA, *P. aeruginosa*, *E. coli* and *S. epidermis* in the presence of sub-lethal concentrations of Manuka honey and under conditions in which antibiotic-resistance would rapidly develop did not lead to the emergence of honey-resistant bacterial strains [10, 35]. These results suggest an important further advantage to use of medical-grade honey products in the context of the rise of antibiotic resistance [10, 35].

CONCLUSION

In conclusion, locally sourced Germania honey is less effective *in vitro* than Manuka honey MGO 550 in killing MRSA from patient wound infections. Further studies could be carried out to determine if Germania honey is more effective against other bacterial species. Use of Manuka honey dressings should be considered in MRSA wound dressing in Saudi Arabia.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The study was approved by the Johns Hopkins Aramco Healthcare Institutional Review Board.

HUMAN AND ANIMAL RIGHTS

No animals/humans were used for studies that are the basis of this research.

CONSENT FOR PUBLICATION

Not applicable.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

The authors wish to acknowledge the use of Johns Hopkins Aramco Healthcare (JHAH) facilities for the data and study for this paper. The opinions expressed in this article are those of the authors and not necessarily of JHAH.

REFERENCES

- [1] El Amin NM, Faidah HS. Methicillin-resistant *Staphylococcus aureus* in the western region of Saudi Arabia: Prevalence and antibiotic susceptibility pattern. *Ann Saudi Med* 2012; 32(5): 513-6. [http://dx.doi.org/10.5144/0256-4947.2012.513] [PMID: 22871621]
- [2] Borgundvaag B, Ng W, Rowe B, Katz K. EMERGENCY Department Emerging Infectious Disease Surveillance Network (EMERGENT) Working Group. Prevalence of methicillin-resistant *Staphylococcus aureus* in skin and soft tissue infections in patients presenting to Canadian emergency Departments. *CJEM* 2013; 15(3): 141-60. [http://dx.doi.org/10.2310/8000.2013.130798] [PMID: 23663462]
- [3] Livermore DM, Mushtaq S, Warner M, James D, Kearns A, Woodford N. Pathogens of skin and skin-structure infections in the UK and their susceptibility to antibiotics, including ceftaroline. *J Antimicrob Chemother* 2015; 70(10): 2844-53. [http://dx.doi.org/10.1093/jac/ckv179] [PMID: 26142478]
- [4] Cardona AF, Wilson SE. Skin and soft-tissue infections: A critical review and the role of telavancin in their treatment. *Clin Infect Dis* 2015; 61(Suppl. 2): S69-78. [http://dx.doi.org/10.1093/cid/civ528] [PMID: 26316560]
- [5] Ray GT, Suaya JA, Baxter R. Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study. *BMC Infect Dis* 2013; 13: 252. [http://dx.doi.org/10.1186/1471-2334-13-252] [PMID: 23721377]
- [6] Henig O, Cober E, Richter SS, et al. Antibacterial Resistance Leadership Group. A prospective observational study of the epidemiology, management, and outcomes of skin and soft tissue infections due to carbapenem-resistant *Enterobacteriaceae*. *Open Forum Infect Dis* 2017; 4(3) [http://dx.doi.org/10.1093/ofid/ofx157] [PMID: 29026866]
- [7] Ruscher C, Pfeifer Y, Layer F, Schaumann R, Levin K, Mielke M. Inguinal skin colonization with multidrug-resistant bacteria among residents of elderly care facilities: Frequency, persistence, molecular analysis and clinical impact. *Int J Med Microbiol* 2014; 304(8): 1123-34. [http://dx.doi.org/10.1016/j.ijmm.2014.08.006] [PMID: 25194858]
- [8] Hoban D, Biedenbach D, Sahn D, Reiszner E, Iaconis J. Activity of ceftaroline and comparators against pathogens isolated from skin and soft tissue infections in Latin America - results of AWARE surveillance 2012. *Braz J Infect Dis* 2015; 19(6): 596-603. [http://dx.doi.org/10.1016/j.bjid.2015.08.011] [PMID: 26481631]
- [9] Alandejani T, Marsan J, Ferris W, Slinger R, Chan F. Effectiveness of honey on *Staphylococcus aureus* and *Pseudomonas aeruginosa* biofilms. *Otolaryngol Head Neck Surg* 2009; 141(1): 114-8. [http://dx.doi.org/10.1016/j.otohns.2009.01.005] [PMID: 19559969]
- [10] Blair SE, Cokcetin NN, Harry EJ, Carter DA. The unusual antibacterial activity of medical-grade *Leptospermum* honey: Antibacterial spectrum, resistance and transcriptome analysis. *Eur J Clin Microbiol Infect Dis* 2009; 28(10): 1199-208. [http://dx.doi.org/10.1007/s10096-009-0763-z] [PMID: 19513768]
- [11] Carter DA, Blair SE, Cokcetin NN, et al. Therapeutic Manuka honey: No longer so alternative. *Front Microbiol* 2016; 7: 569. [http://dx.doi.org/10.3389/fmicb.2016.00569] [PMID: 27148246]
- [12] Cokcetin NN, Pappalardo M, Campbell LT, et al. The antibacterial activity of Australian *Leptospermum* honey correlates with methylglyoxal levels. *PLoS One* 2016; 11(12): e0167780. [http://dx.doi.org/10.1371/journal.pone.0167780] [PMID: 28030589]
- [13] Kilty SJ, Duval M, Chan FT, Ferris W, Slinger R. Methylglyoxal: (active agent of manuka honey) *in vitro* activity against bacterial biofilms. *Int Forum Allergy Rhinol* 2011; 1(5): 348-50. [http://dx.doi.org/10.1002/alar.20073] [PMID: 22287464]
- [14] Brudzynski K, Abubaker K, Wang T. Powerful bacterial killing by buckwheat honeys is concentration-dependent, involves complete DNA degradation and requires hydrogen peroxide. *Front Microbiol* 2012; 3: 242. [http://dx.doi.org/10.3389/fmicb.2012.00242] [PMID: 22783246]
- [15] Biglari B, vd Linden PH, Simon A, Aytac S, Gerner HJ, Moghaddam A. Use of Medihoney as a non-surgical therapy for chronic pressure ulcers in patients with spinal cord injury. *Spinal Cord* 2012; 50(2): 165-9. [http://dx.doi.org/10.1038/sc.2011.87] [PMID: 21931331]
- [16] Natarajan S, Williamson D, Grey J, Harding KG, Cooper RA. Healing of an MRSA-colonized, hydroxyurea-induced leg ulcer with honey. *J Dermatolog Treat* 2001; 12(1): 33-6. [http://dx.doi.org/10.1080/095466301750163563] [PMID: 12171686]
- [17] Simon A, Sofka K, Wiszniewsky G, Blaser G, Bode U, Fleischhack G. Wound care with antibacterial honey (Medihoney) in pediatric hematology-oncology. *Support Care Cancer* 2006; 14(1): 91-7. [http://dx.doi.org/10.1007/s00520-005-0874-8] [PMID: 16075253]
- [18] Lazarides AL, Hamid KS, Kerzner MS. Novel use of active *Leptospermum* honey for ringed fixator pin site care in diabetic Charcot Deformity patients. *Foot Ankle Spec* 2018; 11(2): 117-22. [http://dx.doi.org/10.1177/1938640017709907] [PMID: 28506082]
- [19] Cooper R, Jenkins L, Hooper S. Inhibition of biofilms of *Pseudomonas aeruginosa* by Medihoney *in vitro*. *J Wound Care* 2014; 23(3): 93-96, 98-100, 102 passim. [http://dx.doi.org/10.12968/jowc.2014.23.3.93] [PMID: 24633055]
- [20] Müller P, Alber DG, Turnbull L, et al. Synergism between Medihoney and rifampicin against methicillin-resistant *Staphylococcus aureus* (MRSA). *PLoS One* 2013; 8(2): e57679. [http://dx.doi.org/10.1371/journal.pone.0057679] [PMID: 23469049]
- [21] Liu M, Lu J, Müller P, et al. Antibiotic-specific differences in the response of *Staphylococcus aureus* to treatment with antimicrobials combined with manuka honey. *Front Microbiol* 2015; 5: 779. [http://dx.doi.org/10.3389/fmicb.2014.00779] [PMID: 25674077]
- [22] Packer JM, Irish J, Herbert BR, et al. Specific non-peroxide antibacterial effect of manuka honey on the *Staphylococcus aureus* proteome. *Int J Antimicrob Agents* 2012; 40(1): 43-50. [http://dx.doi.org/10.1016/j.ijantimicag.2012.03.012] [PMID: 22580031]
- [23] Jenkins R, Burton N, Cooper R. Manuka honey inhibits cell division in methicillin-resistant *Staphylococcus aureus*. *J Antimicrob Chemother* 2011; 66(11): 2536-42. [http://dx.doi.org/10.1093/jac/ckr340] [PMID: 21903658]
- [24] Jenkins R, Burton N, Cooper R. Proteomic and genomic analysis of methicillin-resistant *Staphylococcus aureus* (MRSA) exposed to manuka honey *in vitro* demonstrated down-regulation of virulence markers. *J Antimicrob Chemother* 2014; 69(3): 603-15. [http://dx.doi.org/10.1093/jac/dkt430] [PMID: 24176984]
- [25] Jenkins R, Burton N, Cooper R. Effect of manuka honey on the expression of universal stress protein A in methicillin-resistant *Staphylococcus aureus*. *Int J Antimicrob Agents* 2011; 37(4): 373-6. [http://dx.doi.org/10.1016/j.ijantimicag.2010.11.036] [PMID: 21349691]
- [26] Hussain MB, Hannan A, Absar M, Butt N. *In-vitro* susceptibility of methicillin-resistant *Staphylococcus aureus* to honey. *Complement Ther Clin Pract* 2017; 27: 57-60. [http://dx.doi.org/10.1016/j.ctcp.2017.04.003] [PMID: 28438282]
- [27] Sherlock O, Dolan A, Athman R, et al. Comparison of the antimicrobial activity of Ulmo honey from Chile and Manuka honey against methicillin-resistant *Staphylococcus aureus*, *Escherichia coli* and *Pseudomonas aeruginosa*. *BMC Complement Altern Med* 2010; 10: 47. [http://dx.doi.org/10.1186/1472-6882-10-47] [PMID: 20813024]
- [28] Performance standards for antimicrobial susceptibility testing Twenty-eighth informational supplement. Wayne, PA: CLSI 2018; pp. M100-S28.
- [29] Biglari B, Moghaddam A, Santos K, et al. Multicentre prospective observational study on professional wound care using honey (Medihoney™). *Int Wound J* 2013; 10(3): 252-9. [http://dx.doi.org/10.1111/j.1742-481X.2012.00970.x] [PMID: 22494449]
- [30] Forbes TA, Shaw L, Quinlan C. Topical honey in the management of pediatric peritoneal dialysis exit sites. *Perit Dial Int* 2016; 36(6): 684-7. [http://dx.doi.org/10.3747/pdi.2014.00350] [PMID: 27903852]
- [31] Moghnieh R, Alothman AF, Althaqafi AO, et al. Epidemiology and outcome of invasive fungal infections and methicillin-resistant *Staphylococcus aureus* (MRSA) pneumonia and complicated skin and soft tissue infections (cSSTI) in Lebanon and Saudi Arabia. *J Infect Public Health* 2017; 10(6): 849-54. [http://dx.doi.org/10.1016/j.jiph.2017.01.013] [PMID: 28487208]
- [32] Eed EM, Ghonaim MM, Hussein YM, Saber TM, Khalifa AS. Phenotypic and molecular characterization of HA-MRSA in Taif hospitals, Saudi Arabia. *J Infect Dev Ctries* 2015; 9(3): 298-303.

- [33] [http://dx.doi.org/10.3855/jidc.5954] [PMID: 25771468]
Senok A, Ehricht R, Monecke S, Al-Saedan R, Somily A. Molecular characterization of methicillin-resistant *Staphylococcus aureus* in nosocomial infections in a tertiary-care facility: Emergence of new clonal complexes in Saudi Arabia. *New Microbes New Infect* 2016; 14: 13-8.
[http://dx.doi.org/10.1016/j.nmni.2016.07.009] [PMID: 27621823]
- [34] Jenkins RE, Cooper R. Synergy between oxacillin and manuka honey sensitizes methicillin-resistant *Staphylococcus aureus* to oxacillin. *J Antimicrob Chemother* 2012; 67(6): 1405-7.
[http://dx.doi.org/10.1093/jac/dks071] [PMID: 22382468]
- [35] Cooper RA, Jenkins L, Henriques AFM, Duggan RS, Burton NF. Absence of bacterial resistance to medical-grade manuka honey. *Eur J Clin Microbiol Infect Dis* 2010; 29(10): 1237-41.
[http://dx.doi.org/10.1007/s10096-010-0992-1] [PMID: 20549529]

© 2019 Bazzi *et al.*

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (<https://creativecommons.org/licenses/by/4.0/legalcode>). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.